Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Dyne Therapeutics, Inc. - Common Stock
(NQ:
DYN
)
19.99
-0.05 (-0.25%)
Streaming Delayed Price
Updated: 10:57 AM EST, Dec 29, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Dyne Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
Dyne Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
August 12, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
XPeng & QuantumScape Are Among Top 11 Mid Cap Stocks That Performed Well Last Week (July 7-July 13): Details
↗
July 14, 2024
10 mid-cap stocks jumped in last week, including QuantumScape, Lantheus Holdings, Sunrun, Kymera Therapeutics, Apogee Therapeutics, Joby Aviation, Crinetics Pharmaceuticals, Dyne Therapeutics, Summit...
Via
Benzinga
Chart Of The Day: Dyne Therapeutics - Deeply Discounted
↗
July 10, 2024
Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United...
Via
Talk Markets
Dyne Therapeutics Presents New Preclinical Data Demonstrating the Potential of the FORCE™ Platform to Deliver Enzyme Replacement Therapy to Muscle and CNS in Pompe Disease
June 24, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress
June 13, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Casey's Reports Upbeat Earnings, Joins Avidity Biosciences, Rentokil Initial And Other Big Stocks Moving Higher On Wednesday
↗
June 12, 2024
Via
Benzinga
Soft Inflation Data Boosts Small Caps, Real Estate, Regional Banks; Traders Anticipate Fed Rate Cuts As Stocks React
↗
June 12, 2024
U.S. inflation slowed in May, boosting rate cut prospects. Markets rally ahead of FOMC meeting and assign 70% chance of rate cut in September.
Via
Benzinga
Topics
Economy
The 3 Most Undervalued Biotech Stocks to Buy in June 2024
↗
June 04, 2024
https://seekingalpha.com/news/4111624-goldman-sachs-raises-obesity-drug-market-estimate
Via
InvestorPlace
Dyne Therapeutics to Present at Jefferies Global Healthcare Conference
May 30, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
May 28, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Modine Manufacturing Posts Mixed Q4 Results, Joins Viasat, Lululemon And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
↗
May 22, 2024
Via
Benzinga
Dyne Therapeutics Announces Pricing of $325.5 Million Public Offering of Common Stock
May 21, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics Announces Proposed Public Offering of Common Stock
May 20, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Why Is Dyne Therapeutics Stock Soaring On Monday?
↗
May 20, 2024
Dyne Therapeutics reported promising Phase 1/2 trial data for DYNE-101 in myotonic dystrophy type 1 and DYNE-251 in Duchenne muscular dystrophy. Improvements in splicing correction, myotonia, muscle...
Via
Benzinga
Tech Surge Boosts Nasdaq To Record Highs
↗
May 20, 2024
The Nasdaq Composite Index is up triple digits and marking new record highs, thanks to rising tech stocks.
Via
Talk Markets
Topics
Stocks
Why Dyne Therapeutics, With A 108% Run This Year, Just Catapulted Again
↗
May 20, 2024
Dyne Therapeutics is looking to take on Sarepta Therapeutics in DMD.
Via
Investor's Business Daily
Overseas Shipholding, Micron, Squarespace, Incyte And Other Big Stocks Moving Higher On Monday
↗
May 20, 2024
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
↗
May 20, 2024
Pre-market stock movers are a great way to start the trading week and we have all of the hottest news worth reading about on Monday!
Via
InvestorPlace
Dyne Therapeutics Announces New Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Demonstrating Compelling Impact on Key Disease Biomarkers and Improvement in Multiple Functional Endpoints
May 20, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics to Host Virtual Investor Event to Review New Clinical Data from the ACHIEVE and DELIVER Trials Tomorrow, May 20 at 8:00 a.m. ET
May 19, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
DYN Stock Earnings: Dyne Therapeutics Misses EPS for Q1 2024
↗
May 02, 2024
DYN stock results show that Dyne Therapeutics missed analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
May 02, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer
March 27, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium
March 27, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session
↗
March 25, 2024
Shares of Landos Biopharma, Inc. (NASDAQ: LABP) rose sharply during Monday’s session following acquisition news.
Via
Benzinga
Aehr Test Systems Reports Preliminary Results, Joins Dyne Therapeutics, United Airlines And Other Big Stocks Moving Lower On Monday
↗
March 25, 2024
U.S. stocks were lower, with the Dow Jones index falling around 100 points on Monday.
Via
Benzinga
Topics
Stocks
Dyne Therapeutics Announces CEO Transition
March 25, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Neuromuscular Focused-Avidity Biosciences Has 'Complete Package' - Analyst Predicts Stellar 142% Stock Surge
↗
March 14, 2024
Cantor Fitzgerald initiates coverage on Avidity Biosciences highlighting a robust pipeline led by del-desiran, a promising treatment for Myotonic dystrophy type 1. With strong management, proven...
Via
Benzinga
Dyne Therapeutics to Present at Stifel 2024 Virtual CNS Days
March 13, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Chardan Capital Maintains Buy Rating for Dyne Therapeutics: Here's What You Need To Know
↗
March 08, 2024
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
